Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and bevacizumab in advanced non-clear cell renal cell carcinoma
NCT02724878Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2016
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in non-clear cell renal cell carcinoma (nccRCC), sponsored by Dana-Farber Cancer Institute. Started Jul 2016; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT02724878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724878.